Daiwa Securities Group Inc. Sells 18,926 Shares of Moderna, Inc. (NASDAQ:MRNA)

Daiwa Securities Group Inc. decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 27.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,265 shares of the company's stock after selling 18,926 shares during the period. Daiwa Securities Group Inc.'s holdings in Moderna were worth $2,132,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Knuff & Co LLC increased its holdings in Moderna by 5.4% in the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock valued at $316,000 after buying an additional 244 shares during the period. Allworth Financial LP raised its position in Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after purchasing an additional 281 shares in the last quarter. Howard Capital Management Inc. lifted its stake in Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after purchasing an additional 297 shares during the period. Larson Financial Group LLC boosted its stake in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after purchasing an additional 317 shares in the last quarter. Finally, Empowered Funds LLC grew its holdings in shares of Moderna by 6.6% in the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company's stock worth $347,000 after purchasing an additional 322 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Remove Ads

Moderna Stock Performance

MRNA traded down $0.90 on Tuesday, reaching $33.81. The company had a trading volume of 7,055,191 shares, compared to its average volume of 6,553,276. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The company has a market cap of $13.04 billion, a price-to-earnings ratio of -3.64 and a beta of 1.86. The business has a 50 day simple moving average of $35.78 and a 200 day simple moving average of $46.85.

Analysts Set New Price Targets

MRNA has been the subject of several research analyst reports. Argus cut shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. UBS Group cut their price target on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Royal Bank of Canada restated a "sector perform" rating and set a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. JPMorgan Chase & Co. set a $45.00 target price on Moderna in a research report on Friday, February 14th. Finally, Berenberg Bank raised their price target on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Moderna currently has an average rating of "Hold" and an average price target of $59.60.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.